Le Lézard
Classified in: Health
Subject: FEA

Rare and Complex Liver Transplant by Indian Surgeons, 9-month-old Baby From Iraq Gets a New Life


NEW DELHI, Feb. 9, 2021 /PRNewswire/ -- In a rare and complex surgery at HCMCT Manipal Hospitals Delhi, a team of Indian surgeons performed one of the most complex life-saving liver transplant on a nine-month-old boy Ali Hamad who suffered from liver failure due to a rare disorder. Normally, surgeons find it risky for a transplant less than one year of age and 10 kg weight. The team of doctors was headed by Dr. Lalwani, Head of the Department of Liver Transplant and Hepato-Pancreatic-Biliary Surgery and supported by Dr. Lalit Sehgal HOD - General Anesthesia, Liver Transplant Anesthesia, Liver Critical Care, Dr. Vikas Taneja, HOD - Pediatrics and Dr. Sufla Saxena, Consultant - Paediatric Gastroenterologist and Hepatologist. Hamad's mother donated part of her liver to save the life of the baby who was born after her three kids, who perhaps, died of a similar disease that could not be diagnosed and treated timely. 

Baby Hamad was a known case of Progressive Familial Intrahepatic Cholestasis Type II (PFIC TYPE 2). He had jaundice since birth and had multiple hospitalizations in Iraq for jaundice and recurrent cholangitis. Given the history, clinical condition, and pathological diagnosis patient was referred for a liver transplant.

"Hamad was having infection with cholangitis for which he was admitted and treated. Apart from recurrent cholangitis, the patient was having marked ascites and growth failure with a bodyweight of 6.1 kg. He underwent evaluation for a living donor liver transplant and his mother was evaluated as a prospective donor. During an evaluation, CT scan showed cirrhotic changes, hepatosplenomegaly with attenuated portal vein with no portal flow with significant ascites and significant portosystemic collaterals," said Dr. Lalawani 

On 3rd January 2021, the baby underwent a transplant. "There was no flow in the portal vein. We placed the interposition vein graft to give inflow to the liver. It took around 9 hours to complete the transplant and baby was shifted to ICU on a ventilator," said Dr. Lalwani.

The baby was off the ventilator the next morning and gradually in the next few days, he started accepting oral feed, tolerating well, and gaining weight. Finally, after 20 days of surgery baby was discharged from the hospital. The family plans to go back to Iraq.

About Manipal Hospitals: Manipal Hospitals is among the largest hospital network in India serving over 2million patients annually. It is first in India to be awarded accreditation by the AAHRPP for ethical standards in clinical research activities. It is also NABL, NABH and ISO certified.

For more details contact:

Manish Bakshi +91-7014677837
[email protected]
[email protected]

 

SOURCE Manipal Hospitals


These press releases may also interest you

at 03:14
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...

10 mai 2024
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

10 mai 2024
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

10 mai 2024
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

10 mai 2024
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

10 mai 2024
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...



News published on and distributed by: